TRO 19622|cas 22033-87-0|DC Chemicals

TRO 19622|cas 22033-87-0|DC Chemicals

TRO19622, a small cholesterol-like molecule, is a neuroregenerative and neuroprotective compound.

IC50 Value: 3.2 ± 0.2 μM(EC50) [1]

Target: Others

in vitro: TRO19622 maintained survival of 74 ± 10% (n = 8) of the neurons supported by a cocktail of trophic factors (1 ng/ml brain-derived neurotrophic factor, 1 ng/ml glia-derived neurotrophic factor, and 10 ng/ml ciliary neurotrophic factor), defined as 100%.

Product Name: TRO 19622|Cat No: DC9538|Cas: 22033-87-0|Molecule Formular: C27H45NO|Molecule Weight: 399.6523|Other names: TRO 19622

TRO19622, a small cholesterol-like molecule, is a neuroregenerative and neuroprotective compound.
in vitro: TRO19622 maintained survival of 74 ± 10% (n = 8) of the neurons supported by a cocktail of trophic factors (1 ng/ml brain-derived neurotrophic factor, 1 ng/ml glia-derived neurotrophic factor, and 10 ng/ml ciliary neurotrophic factor), defined as 100%. increased overall neurite outgrowth per cell by 54%. Olesoxime prevented neurite shrinkage induced by MTAs in differentiated PC-12 and SK-N-SH neuroblastoma cell lines by up to 90%. Olesoxime also counteracted MTA inhibition of microtubule-dependent mitochondria trafficking.
in vivo: Treatment with TRO19622(3 mg/kg/day) resulted in a significant increase in life span. TRO19622-treated SOD1G93A mice lived 10% longer (138 ± 4 days, n = 7 and 135 ± 3 days, n = 7, for doses of 3 and 30 mg/kg/day, respectively) than did vehicle-treated controls (125 ± 3 days, n = 9) [1]. TRO19622 was also able to reverse tactile allodynia in vincristine-treated rats, a model of chemotherapy-induced neuropathic pain. Olesoxime targets mitochondrial proteins and its effects are consistent with the mitotoxicity hypothesis for paclitaxel-evoked painful peripheral neuropathy. Olesoxime may be useful clinically for both the prevention and treatment of paclitaxel-evoked painful peripheral neuropathy. Phase I clinical trials of olesoxime have been completed successfully. Olesoxime is well tolerated and achieves levels predicted to be clinically effective when administered orally.

For research only, not for human use!